New nanoparticle vaccine against chikungunya enters first human tests
⭐️ VACCINE ⭐️
Not yet recruiting
This early-stage trial tests a new vaccine called PepGNP-ChikV that uses tiny particles to train the immune system against the chikungunya virus. About 40 healthy adults aged 18 to 60 will receive two shots, 42 days apart, and be monitored for safety and immune response for a yea…
Phase: EARLY_PHASE1 • Sponsor: Gylden Pharma Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated May 01, 2026 15:57 UTC